Dysregulated Signalling Pathways Driving Anticancer Drug Resistance
International Journal of Molecular Sciences · 30.07.2023 · 24 (15) · 12222
DOI: 10.3390/ijms241512222 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.07.2023. Verfasst von Nauf Bou Antoun und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences Pharmacy and Chemistry, Biomolecular Sciences Department, Kingston University London, Kingston-upon-Thames KT1 2EE, UK. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 111-mal zitiert (Crossref) und nennt 324 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
One of the leading causes of death worldwide, in both men and women, is cancer. Despite the significant development in therapeutic strategies, the inevitable emergence of drug resistance limits the success and impedes the curative outcome. Intrinsic and acquired resistance are common mechanisms responsible for cancer relapse. Several factors crucially regulate tumourigenesis and resistance, including physical barriers, tumour microenvironment (TME), heterogeneity, genetic and epigenetic alterations, the immune system, tumour burden, growth kinetics and undruggable targets. Moreover, transforming growth factor-beta (TGF-β), Notch, epidermal growth factor receptor (EGFR), integrin-extracellular matrix (ECM), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), phosphoinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR), wingless-related integration site (Wnt/β-catenin), Janus kinase/signal transducers and activators of transcription (JAK/STAT) and RAS/RAF/mitogen-activated protein kinase (MAPK) signalling pathways are some of the key players that have a pivotal role in drug resistance mechanisms. To guide future cancer treatments and improve results, a deeper comprehension of drug resistance pathways is necessary. This review covers both intrinsic and acquired resistance and gives a comprehensive overview of recent research on mechanisms that enable cancer cells to bypass barriers put up by treatments, and, like “satellite navigation”, find alternative routes by which to carry on their “journey” to cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences Pharmacy and Chemistry, Biomolecular Sciences Department, Kingston University London, Kingston-upon-Thames KT1 2EE, UK.
Zitieren
APA
Bou Antoun, N., & Chioni, A. M. (2023). Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. International Journal of Molecular Sciences, 24(15), 12222. https://doi.org/10.3390/ijms241512222
Vancouver
Bou Antoun N, Chioni AM. Dysregulated Signalling Pathways Driving Anticancer Drug Resistance. International Journal of Molecular Sciences. 2023;24(15):12222. doi:10.3390/ijms241512222
BibTeX
@article{BouAntoun2023,
author = {Bou Antoun, Nauf and Chioni, Athina-Myrto},
title = {Dysregulated Signalling Pathways Driving Anticancer Drug Resistance},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {15},
pages = {12222},
doi = {10.3390/ijms241512222}
}
EUVIMED